By Turna Ray
Announcing its third personalized medicine pact this month, biopharmaceutical services provider Quintiles has jumped head-first into the genomically guided drug development space.

This week, Quintiles announced it would collaborate with pharmacogenetics firm London Genetics to provide personalized medicine services to drug developers. Financial terms of the deal were not disclosed.

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.